Dean Pepol has been intimately acquainted with the challenges of prostate cancer, a disease that ranks as the second-leading cause of cancer-related deaths among American men. His family history of prostate cancer, including his father’s diagnosis, prompted Pepol to diligently monitor his prostate-specific antigen (PSA) levels through regular physical exams. In 2006, Pepol received unsettling news as his PSA levels indicated the presence of an aggressive form of prostate cancer. Subsequently, he underwent a radical prostatectomy and pursued innovative intensity-modulated radiation therapy to manage the disease for eight years.
Despite initial treatment success, Pepol faced a setback in 2014 when his cancer progressed to Stage 4, necessitating a change in treatment approach. Over the years, he explored various therapies across different states, participating in clinical trials and demonstrating unwavering resilience in the face of a relentless adversary. His journey led him to Johns Hopkins Medicine, where he sought treatment at the Theranostics Center within the Department of Radiology and Radiological Science, renowned for its pioneering work in theranostics, a cutting-edge approach that combines imaging and molecular radiotherapy to target specific cancer cells.
At Johns Hopkins Medicine, Pepol was enrolled in a clinical trial for a novel radiopharmaceutical drug, lutetium Lu 177 vipivotide tetraxetan (Pluvicto), which had recently received FDA approval for prostate cancer therapy. This targeted therapy, designed to address the overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells, yielded remarkable results for Pepol. Dr. Andrei Gafita, an expert at the Theranostics Center, highlighted the significance of such personalized treatments in revolutionizing prostate cancer care, emphasizing the pivotal role of research funding from institutions like the National Institutes of Health (NIH) and the Prostate Cancer Foundation in driving therapeutic advancements.
The collaborative efforts and federally funded research initiatives at Johns Hopkins Medicine have been pivotal in advancing the field of prostate cancer treatment, particularly through the development of innovative imaging techniques and targeted therapies. Dr. Lilja Solnes, a key figure in nuclear medicine and molecular imaging at Johns Hopkins, emphasized the role of NIH funding in fueling groundbreaking research that translates into tangible clinical benefits for patients like Pepol. The success of theranostics in improving patient outcomes and quality of life underscores the transformative impact of academic research centers in driving therapeutic innovation.
Following his treatment with lutetium Lu 177 vipivotide tetraxetan at the Theranostics Center, Pepol experienced a period of stability in his cancer progression and quality of life. However, as his disease evolved, necessitating additional interventions, Pepol’s care team at Johns Hopkins Medicine remained steadfast in their commitment to his well-being. Through a voucher program facilitated by the Theranostics Center, Pepol received supplementary treatments, leading to a significant reduction in his PSA levels and renewed hope for continued treatment success. His journey exemplifies the resilience and collaborative spirit that define the ethos of Johns Hopkins Medicine in confronting complex oncological challenges.
In May 2025, following his latest treatment at Johns Hopkins, Pepol witnessed a decline in his PSA levels, signaling a positive response to the therapy. With plans for further treatment in August 2025, Pepol remains grateful for the unwavering support and expertise of his care team at the Theranostics Center. The compassionate and personalized care provided by his clinicians has been instrumental in navigating his challenging medical journey, underscoring the profound impact of a multidisciplinary approach to cancer care. Pepol’s story serves as a testament to the transformative potential of theranostics and innovative cancer treatments in offering hope and extending the lives of patients battling advanced prostate cancer.
- Theranostics, combining imaging and molecular radiotherapy, offers personalized and effective treatment for prostate cancer patients.
- Collaborative research efforts and NIH funding drive therapeutic innovations in prostate cancer care.
- Successful outcomes at academic centers like Johns Hopkins Medicine highlight the pivotal role of research in improving patient quality of life.
- Pepol’s journey underscores the resilience and transformative impact of personalized cancer treatments, emphasizing the importance of comprehensive care in complex oncological cases.
Tags: theranostics, clinical trials
Read more on hopkinsmedicine.org